Gilead scores US approval for breast cancer drug that wowed ESMO

cafead

Administrator
Staff member
  • cafead   Apr 08, 2021 at 10:42: AM
via Gilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug has now been approved by the FDA for triple-negative breast cancer.

article source
 

<